- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
First XPS™ installed in China
China is currently the fastest growing lung transplant market in the world, with a 37% increase in lung transplants in 2016 (201 lung transplants performed). Due to the increased need for lung transplantation the number of clinics authorized to perform lung transplants has increased from 20 clinics in 2016 to 27 clinics in 2017. In parallel with the transplant centers growth, the organ donation system in China is also growing to meet this lifesaving demand. The current donor system is an OPO system, with the expectation to take advantage of increased utilization of marginal lungs for transplant. The end point of this collaboration is to reduce mortality on the waiting list.
The Lung Transplantation program lead by Professor Jiang Gening will head the first EVLP- study in China that will investigate the effects of EVLP on Lung transplantation. The study design is an investigator initiated single center trial with the intention to add Chinese data to the existing EVLP data from North America and Europe. The company plans to initiate a registration process of the XPS™ with the CFDA. In partnership with XVIVO Perfusion´s Distributor in China (Genext Ltd), we plan to scientifically support the Lung transplant clinic at Shanghai Pulmonary Hospital, the leading hospital in treatment of lung diseases in China. The hospital has over 1,000 beds and performed more than 10,000 thoracic surgery operations last year. With the addition of the XVIVO XPS™ system the Shanghai Pulmonary Hospital fully expects to become the EVLP Center of Excellence in Asia.
“We are delighted that we delivered the first XPS to China with the intention of a clinical study. China has put a lot of effort in increasing the number of transplants performed, and it has from a low level resulted in rapid growth in the past three years. Considering the size of the population and the fast increase in the standard of living and healthcare, China is expected to become an important market for XVIVO in a not too distant future”, says Magnus Nilsson, CEO of XVIVO Perfusion.
December 1, 2017
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on December 1, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.